Emcure Pharmaceuticals Completes Acquisition, Makes Gennova Biopharmaceuticals Wholly-Owned Subsidiary
Emcure Pharmaceuticals Limited has successfully completed the acquisition of remaining shares in Gennova Biopharmaceuticals Limited, making the biotechnology firm a wholly-owned subsidiary of Emcure. The transaction involved acquiring 663,865 Equity Shares, constituting 12.05% of the total issued and paid up capital of Gennova Biopharmaceuticals Limited.The completion of the acquisition means that Gennova is now fully integrated into Emcure’s corporate structure. This follows an earlier agreement for the acquisition in which Emcure had been acquiring shares from individual shareholders of the company. The aggregate consideration for the purchase of these shares was Rs. 2,318.7 Million, which was paid in cash.
Prior to this final transaction, Emcure held a controlling stake of 87.95% in Gennova. Post-acquisition, Emcure's shareholding in Gennova will stand at 100%.
Gennova Biopharmaceuticals Limited is involved in the research and development, manufacturing, and marketing of biotechnology-based products. The company was incorporated on June 19, 2001.
Key details regarding Gennova Biopharmaceuticals Limited are provided below:
| Particulars | Information |
|---|---|
| Industry | Pharmaceuticals |
| Nature of Business | Research and development, manufacturing, and marketing of biotechnology-based products |
| FY 2026 Turnover | Rs. 4,917.42 Million |
| FY 2026 PAT | Rs. 54.25 Million |
| Incorporation Date | June 19, 2001 |
The company's turnover across the last three financial years stands as follows:
| Financial Year | Turnover (Rs. Million) |
|---|---|
| FY 2025-26 | Rs. 4,917.42 |
| FY 2024-25 | Rs. 4,299.46 |
| FY 2023-24 | Rs. 4,220.82 |
The completion of the acquisition resulted in Gennova becoming a wholly-owned entity within Emcure Pharmaceuticals Limited.
EMCURE Stock Price Movement
Emcure Pharmaceuticals Limited shares shed 1.97% during trading on Wednesday, settling at ₹1889.2 after the equity had briefly touched its 52-week high. The stock saw a decline of ₹38.00 from the previous close and traded a volume of 110,499 shares in the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.